Guggenheim Securities adjusted its financial outlook for shares of AbbVie Inc . (NYSE:ABBV), reducing the price target to $212 from the previous $221, while still recommending a Buy rating for the ...

ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock’s valuation.

AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of ...

We recently published a list of 10 Best Dividend Kings Stocks to Invest in Now. In this article, we are going to take a look ...

Here's what you need to know about this stock to decide whether you want to own it. AbbVie is notable among the major pharma businesses for its smooth execution of its carefully planned pipeline ...

AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

AbbVie Inc. closed $31.77 below its 52-week high ($207.32), which the company reached on October 31st.

AbbVie is a stellar business, which is extremely undervalued. A stock like ABBV certainly deserves a premium over the fair share price but it currently trades with a 17% discount making it a no ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on ABBV stock, giving a Buy rating yesterday.Stay Ahead of the ...

Like Bristol-Myers Squibb And AbbVie, Johnson & Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion Deal Johnson & Johnson's $14.6 billion acquisition of Intra-Cellular Therapies ...